Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jan 2016
Randomized Controlled TrialApremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
In the phase III double-blind Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in moderate to severe psoriasis. ⋯ Apremilast reduces the severity of nail/scalp psoriasis.